Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors

Overview

Journal Mol Diagn Ther

Specialties Molecular Biology
Pathology
Pharmacology

Date 2024 Aug 22

PMID 39172329

Authors

Yuheng Gu

Qi Zhao

Affiliations

Soon will be listed here.

Abstract

In recent years, bispecific antibodies (BsAbs) have emerged as a promising therapeutic strategy against tumors. BsAbs can recruit and activate immune cells, block multiple signaling pathways, and deliver therapeutic payloads directly to tumor sites. This review provides a comprehensive overview of the recent advances in the development and clinical application of BsAbs for the treatment of solid tumors. We discuss the different formats, the unique mechanisms of action, and the clinical outcomes of the most advanced BsAbs in solid tumor therapy. Several studies have also analyzed the clinical progress of bispecific antibodies. However, this review distinguishes itself by exploring the challenges associated with bispecific antibodies and proposing potential solutions. As the field progresses, BsAbs hold promise to redefine cancer treatment paradigms and offer new hope to patients with solid tumors.

References

Roy P, Saikia B . Cancer and cure: A critical analysis. Indian J Cancer. 2017; 53(3):441-442. DOI: 10.4103/0019-509X.200658. View

Dougan M, Dranoff G, Dougan S . Cancer Immunotherapy: Beyond Checkpoint Blockade. Annu Rev Cancer Biol. 2023; 3:55-75. PMC: 10400018. DOI: 10.1146/annurev-cancerbio-030518-055552. View

Suurs F, Lub-de Hooge M, de Vries E, de Groot D . A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacol Ther. 2019; 201:103-119. DOI: 10.1016/j.pharmthera.2019.04.006. View

Perez P, Hoffman R, Shaw S, Bluestone J, Segal D . Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature. 1985; 316(6026):354-6. DOI: 10.1038/316354a0. View

Rader C . Bispecific antibodies in cancer immunotherapy. Curr Opin Biotechnol. 2019; 65:9-16. PMC: 7292752. DOI: 10.1016/j.copbio.2019.11.020. View

Middelburg J, Kemper K, Engelberts P, Labrijn A, Schuurman J, van Hall T . Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors. Cancers (Basel). 2021; 13(2). PMC: 7829968. DOI: 10.3390/cancers13020287. View

Scott A, Wolchok J, Old L . Antibody therapy of cancer. Nat Rev Cancer. 2012; 12(4):278-87. DOI: 10.1038/nrc3236. View

Ma H, OKennedy R . The Structure of Natural and Recombinant Antibodies. Methods Mol Biol. 2015; 1348:7-11. DOI: 10.1007/978-1-4939-2999-3_2. View

Brinkmann U, Kontermann R . The making of bispecific antibodies. MAbs. 2017; 9(2):182-212. PMC: 5297537. DOI: 10.1080/19420862.2016.1268307. View

10.

Labrijn A, Janmaat M, Reichert J, Parren P . Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019; 18(8):585-608. DOI: 10.1038/s41573-019-0028-1. View

11.

Birch J, Racher A . Antibody production. Adv Drug Deliv Rev. 2006; 58(5-6):671-85. DOI: 10.1016/j.addr.2005.12.006. View

12.

Lowe D, Dudgeon K, Rouet R, Schofield P, Jermutus L, Christ D . Aggregation, stability, and formulation of human antibody therapeutics. Adv Protein Chem Struct Biol. 2011; 84:41-61. DOI: 10.1016/B978-0-12-386483-3.00004-5. View

13.

Shim H . Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations. Biomolecules. 2020; 10(3). PMC: 7175114. DOI: 10.3390/biom10030360. View

14.

Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W . Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J Mol Biol. 2010; 399(3):436-49. DOI: 10.1016/j.jmb.2010.04.001. View

15.

Han S, Shin H, Lee J, Liu Z, Rabadan R, Lee J . Secretome analysis of patient-derived GBM tumor spheres identifies midkine as a potent therapeutic target. Exp Mol Med. 2019; 51(12):1-11. PMC: 6897967. DOI: 10.1038/s12276-019-0351-y. View

16.

Wang X, Mathieu M, Brezski R . IgG Fc engineering to modulate antibody effector functions. Protein Cell. 2017; 9(1):63-73. PMC: 5777978. DOI: 10.1007/s13238-017-0473-8. View

17.

Coloma M, Morrison S . Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol. 1997; 15(2):159-63. DOI: 10.1038/nbt0297-159. View

18.

Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A . Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol. 2007; 25(11):1290-7. DOI: 10.1038/nbt1345. View

19.

Hambach J, Mann A, Bannas P, Koch-Nolte F . Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors. Front Immunol. 2022; 13:1005800. PMC: 9668101. DOI: 10.3389/fimmu.2022.1005800. View

20.

Yu F, Gudmundsdotter L, Akal A, Gunneriusson E, Frejd F, Nygren P . An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo. MAbs. 2014; 6(6):1598-607. PMC: 4622551. DOI: 10.4161/mabs.36089. View